PT - JOURNAL ARTICLE AU - Butzin-Dozier, Zachary AU - Qiu, Sky AU - Hubbard, Alan E. AU - Shi, Junming (Seraphina) AU - van der Laan, Mark J. TI - Highly adaptive LASSO: Machine learning that provides valid nonparametric inference in realistic models AID - 10.1101/2024.10.18.24315778 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.18.24315778 4099 - http://medrxiv.org/content/early/2024/10/19/2024.10.18.24315778.short 4100 - http://medrxiv.org/content/early/2024/10/19/2024.10.18.24315778.full AB - Understanding treatment effects on health-related outcomes using real-world data requires defining a causal parameter and imposing relevant identification assumptions to translate it into a statistical estimand. Semiparametric methods, like the targeted maximum likelihood estimator (TMLE), have been developed to construct asymptotically linear estimators of these parameters. To further establish the asymptotic efficiency of these estimators, two conditions must be met: 1) the relevant components of the data likelihood must fall within a Donsker class, and 2) the estimates of nuisance parameters must converge to their true values at a rate faster than n−1/4. The Highly Adaptive LASSO (HAL) satisfies these criteria by acting as an empirical risk minimizer within a class of càdlàg functions with a bounded sectional variation norm, which is known to be Donsker. HAL achieves the desired rate of convergence, thereby guaranteeing the estimators’ asymptotic efficiency. The function class over which HAL minimizes its risk is flexible enough to capture realistic functions while maintaining the conditions for establishing efficiency. Additionally, HAL enables robust inference for non-pathwise differentiable parameters, such as the conditional average treatment effect (CATE) and causal dose-response curve, which are important in precision health. While these parameters are often considered in machine learning literature, these applications typically lack proper statistical inference. HAL addresses this gap by providing reliable statistical uncertainty quantification that is essential for informed decision-making in health research.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the National Institute for Allergy and Infectious Diseases (1K01AI182501-01 to Zachary Butzin-Dozier) and a global development grant (OPP1165144) from the Bill and Melinda Gates Foundation to the University of California, Berkeley, CA, USA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data used in and produced by the present study are available upon request.